- Home
- SATX vs HLVX Comparison
SATX vs HLVX Comparison
Compare SATX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATX
- HLVX
- Stock Information
- Founded
- SATX 2012
- HLVX 2020
- Country
- SATX Israel
- HLVX United States
- Employees
- SATX N/A
- HLVX N/A
- Industry
- SATX Radio And Television Broadcasting And Communications Equipment
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- SATX Technology
- HLVX Health Care
- Exchange
- SATX Nasdaq
- HLVX Nasdaq
- Market Cap
- SATX 177.6M
- HLVX 83.7M
- IPO Year
- SATX N/A
- HLVX 2022
- Fundamental
- Price
- SATX $2.04
- HLVX $1.91
- Analyst Decision
- SATX Strong Buy
- HLVX Hold
- Analyst Count
- SATX 2
- HLVX 5
- Target Price
- SATX $2.25
- HLVX $2.33
- AVG Volume (30 Days)
- SATX 406.1K
- HLVX 298.1K
- Earning Date
- SATX 05-22-2025
- HLVX 05-08-2025
- Dividend Yield
- SATX N/A
- HLVX N/A
- EPS Growth
- SATX N/A
- HLVX N/A
- EPS
- SATX N/A
- HLVX N/A
- Revenue
- SATX $20,648,000.00
- HLVX N/A
- Revenue This Year
- SATX $50.67
- HLVX N/A
- Revenue Next Year
- SATX $1.64
- HLVX N/A
- P/E Ratio
- SATX N/A
- HLVX N/A
- Revenue Growth
- SATX 92.43
- HLVX N/A
- 52 Week Low
- SATX $0.53
- HLVX $1.34
- 52 Week High
- SATX $2.39
- HLVX $16.31
- Technical
- Relative Strength Index (RSI)
- SATX 65.56
- HLVX 61.71
- Support Level
- SATX $1.99
- HLVX $1.81
- Resistance Level
- SATX $2.02
- HLVX $1.94
- Average True Range (ATR)
- SATX 0.03
- HLVX 0.10
- MACD
- SATX -0.02
- HLVX 0.01
- Stochastic Oscillator
- SATX 87.50
- HLVX 83.87
About SATX SatixFy Communications Ltd.
SatixFy Communications Ltd is engaged in developing end-to-end next-generation satellite communication systems. This includes satellite payloads, user terminals, and modems, which are built on powerful in-house designed chipsets. Their products feature modems equipped with Software Defined Radio and Fully Electronically Steered Multi Beam Antennas that support the entire DVB-RCS2 / DVB-S2X industry standards as well as a complete SDR for any other waveform. The company has a geographical presence in the U.S. & Canada, the UK, and Other countries, with the majority of its revenue generated from the U.S. and Canada.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.